MA29432B1 - Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques - Google Patents

Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques

Info

Publication number
MA29432B1
MA29432B1 MA30221A MA30221A MA29432B1 MA 29432 B1 MA29432 B1 MA 29432B1 MA 30221 A MA30221 A MA 30221A MA 30221 A MA30221 A MA 30221A MA 29432 B1 MA29432 B1 MA 29432B1
Authority
MA
Morocco
Prior art keywords
compounds
glucagon receptor
preparation
methods
receptor antagonists
Prior art date
Application number
MA30221A
Other languages
English (en)
Inventor
Mark Donald Chappell
Scott Eugene Conner
Allie Edward Tripp
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29432(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA29432B1 publication Critical patent/MA29432B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA PRÉSENTE INVENTION CONCERNE DES NOUVEAUX COMPOSÉS DE FORMULE (I) OU DES SELS ASSOCIÉS ACCEPTABLES PHARMACEUTIQUEMENT QUI POSSÈDENT UN ANTAGONISTE DU RÉCEPTEUR DU GLUCAGON OU UNE ACTIVITÉ AGONISTE INVERSE, AINSI QUE DES MÉTHODES D'UTILISATION DE CES COMPOSÉS ET INTERMÉDIAIRES ET DES MÉTHODES DE PRÉPARATION DE TELS COMPOSÉS. DANS UN AUTRE MODE DE RÉALISATION, CETTE INVENTION A POUR OBJET DES COMPOSITIONS PHARMACEUTIQUES RENFERMANT DES COMPOSÉS DE FORMULE (I), AINSI QUE DES MÉTHODES LES EMPLOYANT DANS LE TRAITEMENT DE TROUBLES DIABÉTIQUES ET D'AUTRES TROUBLES MÉTABOLIQUES LIÉS AU GLUCAGON, ET SIMILAIRE.
MA30221A 2005-02-11 2007-09-11 Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques MA29432B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11

Publications (1)

Publication Number Publication Date
MA29432B1 true MA29432B1 (fr) 2008-05-02

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30221A MA29432B1 (fr) 2005-02-11 2007-09-11 Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques

Country Status (25)

Country Link
US (1) US8084489B2 (fr)
EP (1) EP1856090B1 (fr)
JP (1) JP4988604B2 (fr)
KR (1) KR20070104409A (fr)
CN (1) CN101115735B (fr)
AT (1) ATE445609T1 (fr)
AU (1) AU2006213894B2 (fr)
BR (1) BRPI0607015A2 (fr)
CA (1) CA2597073C (fr)
CR (1) CR9304A (fr)
CY (1) CY1109624T1 (fr)
DE (1) DE602006009773D1 (fr)
DK (1) DK1856090T3 (fr)
EA (1) EA200701705A1 (fr)
ES (1) ES2332470T3 (fr)
IL (1) IL184932A0 (fr)
MA (1) MA29432B1 (fr)
MX (1) MX2007009661A (fr)
NO (1) NO20074567L (fr)
PL (1) PL1856090T3 (fr)
PT (1) PT1856090E (fr)
SI (1) SI1856090T1 (fr)
TN (1) TNSN07313A1 (fr)
WO (1) WO2006086488A2 (fr)
ZA (1) ZA200706354B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2337596T3 (es) * 2004-06-14 2010-04-27 Eli Lilly And Company Antagonistas del receptor de glucacion, preparacion y usos terapeuticaos.
ES2720430T3 (es) 2007-02-09 2019-07-22 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagón
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8907103B2 (en) 2008-08-13 2014-12-09 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR112013016033A2 (pt) 2010-12-23 2018-06-05 Pfizer moduladores do receptor de glucagon
IL227559A (en) 2011-02-08 2016-04-21 Pfizer Glucagon receptor modulator
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2013014569A1 (fr) 2011-07-22 2013-01-31 Pfizer Inc. Modulateurs des récepteurs de quinolinylglucagon
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
EP3065736B1 (fr) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Composés antagonistes du récepteur du glucagon, compositions correspodantes et méthodes d'utilisation
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
WO2017049140A2 (fr) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Analogues d'angiotensine (1-7) et procédés associés
CA2914601A1 (fr) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Analogues d'angiotensine-(1-7) et methodes associees
MA46089A (fr) 2016-08-30 2019-07-10 Regeneron Pharma Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon
EP3529278A1 (fr) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Méthodes d'abaissement de niveaux de glycémie
MX2020002057A (es) 2017-08-22 2020-07-13 Regeneron Pharma Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
CR20220294A (es) 2019-12-20 2022-08-03 Bayer Ag Tiofenocarboxamidas sustituidas y sus derivados

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511683A (ja) * 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
WO2004002480A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Nouveaux antagonistes/agonistes inverses du glucagon
ES2428538T3 (es) * 2004-05-28 2013-11-08 Eli Lilly And Company Antagonistas del receptor de glucagón, preparación y usos terapéuticos
ES2337596T3 (es) 2004-06-14 2010-04-27 Eli Lilly And Company Antagonistas del receptor de glucacion, preparacion y usos terapeuticaos.

Also Published As

Publication number Publication date
PL1856090T3 (pl) 2010-02-26
PT1856090E (pt) 2009-11-18
IL184932A0 (en) 2007-12-03
ZA200706354B (en) 2008-11-26
CY1109624T1 (el) 2014-08-13
MX2007009661A (es) 2007-09-25
NO20074567L (no) 2007-11-08
DE602006009773D1 (de) 2009-11-26
US8084489B2 (en) 2011-12-27
SI1856090T1 (sl) 2010-02-26
ATE445609T1 (de) 2009-10-15
CN101115735A (zh) 2008-01-30
CA2597073A1 (fr) 2006-08-17
AU2006213894B2 (en) 2011-12-08
AU2006213894A1 (en) 2006-08-17
JP4988604B2 (ja) 2012-08-01
EA200701705A1 (ru) 2008-02-28
JP2008530102A (ja) 2008-08-07
ES2332470T3 (es) 2010-02-05
DK1856090T3 (da) 2009-11-30
KR20070104409A (ko) 2007-10-25
US20100137417A1 (en) 2010-06-03
WO2006086488A3 (fr) 2006-12-14
EP1856090B1 (fr) 2009-10-14
BRPI0607015A2 (pt) 2009-12-01
CR9304A (es) 2008-03-31
EP1856090A2 (fr) 2007-11-21
CN101115735B (zh) 2013-01-09
WO2006086488A2 (fr) 2006-08-17
TNSN07313A1 (en) 2008-12-31
CA2597073C (fr) 2014-11-25

Similar Documents

Publication Publication Date Title
MA29432B1 (fr) Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
WO2007120270A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης